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Safety Management 
UMS Safety Management (SM), in partnership w ith the UMaine Office of Research Compliance, works w ith researchers to encourage and 
Sl1pport the safety of employees throughout the state and beyond. Safety Management supports the research commlmity in a multit ude 
of ways including; working with UMaine and UMS Human Resources, UMS Risk Management, and the UMaine researcher's chain of 
command. 
Some more detailed examples include: examining job descriptions with Human Resources (HR), assisting supervisors with the evaluation of 
the health and safety checklists, conducting site visits for Pr incipal Investigators, performing client observations for the Office of Research 
Compliance, reviewing Fieldwork Hazard Assessments and Safety Plans, answering specialized or unique occupational safety train ing 
questions for personnel, and monitoring chemical purchases behind t he scenes. SM supports the UMaine chain of command by 
remaining active on organized committees (e.g., UMaine Radiation Safety Committee, Institut ional BiosafetY. Committee, and Institutional 
Animal Care and Use Committee) which help link the compliance structure between the campus and the system. 
In addition to the aforementioned activit ies, SM also receives Proposal Approval Routing System (PARS) notifications surrounding 
specialized or unique concerns that UMaine research has chosen to address directly. Some examples are: 
• The use of radioactive isotopes (e.g. benchtop or field work), equipment containing radioactive materials (sealed sources), or ionizing 
radiation-producing equipment (e.g. electron microscopes, x-ray equipment) 
• The use of Class 3b or 4 lasers 
• Activities which require medical evaluations for potent ial exposure to Particularly Hazardous Substances defined in the UMS chemical 
hygiene 12lan temP-late, specific OSHA regulated substances (e.g. lead, asbestos), and pesticides (e.g. acute toxicity single exposure 
category 1. and 2) 
• Any project activities involve human underwater activit ies (scuba diving, hookah diving, or breath-hold/free diving) 
• Activities where respiratory protection (Self Contained Breathing Apparatus, elastomeric or filter ing face piece respirators) are 
necessary clue to health exposures or lack of engineer ing controls (chemical fume hoods) in place 
• Activities which have excessive noise in excess of 85db (e.g. having to shout or raise your voice when w ithin 6' of another person) 
• Activities which require interaction with human blood, tuberculosis, wild animals, possible exposure to zoonotic diseases and 
infectious material 
• Activities which require special SM train ing re~uirements 
• Activities which generate hazardous waste paid for through indirect cost recovery 
SM may reach out by way of automatic emails through PARS or directly from Safety Management. The guidance and suggestions provided 
in those communications are only as good as the information you provide as an input to PARS. If you are working with the concerns above, 
and have had no contact w ith SM post 3 weeks from submitting your r esearch proposal, contact safety management at sem@maine.edu. 
It is especially important to verify that the SM recommendations have been completed prior to grant award to prevent 
interruptions or postponements to your research. If you are work ing with the noted concerns above, and not involved with PARS, you 
should also be proactively communicating with your chain of command and UMS Safety Management. 
For more information (such as Policies/Guidance/Programs, tra ining information, and SM Staff) please visit the Safety'. Management 
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Forms & Resources 
IBCFAQs 
Institutional Biosafety Commitee (IBC) 
Institutional Biosafety Committee (IBC} registration is required prior to use of 'biohazards' 
in research. Under UMaine policy, 'biohazard' includes recombinant or synthetic nucleic 
acid molecules (including plants), biological materials/biospecimens (human and animal 
blood, bodily fluids, and/or tissues), infectious agents* or select agents/ toxins. (*The 
University of Maine has defined "infectious agents" as all bacterial, parasitic, fungal, viral, 
and prion, included within Class 2 or higher classes; See Appendix B of NIH Guidelines.) 
For guidance on whether your biohazards work requires IBC or other approvals, view 
the IBC Protocol Submission Decision Tree. 
Questions regarding the IBC may be directed to umric@maine.edu. 
May 15, 2.020 Update from the NIH Office of Science Policy: The 
NIH Office of Science Policy has issued Frequently Asked Questions 
(FAQs) regarding interim biosafety guidance for research with SARS-
CoV-2 and relevant Institutional Biosafety Committee (IBC) 
requirements under the NIH Guidelines. Appendix B of the NIH 
Guidelines provides the basis for the classification of biohazardous 
agents by Risk Group (RG). At the present time, SARS-CoV-2 best 
meets the definit ion of a RG3 agent and IBCs should consider the 
agent to be RG3 as a starting point in their risk assessments when 
reviewing research subject to the NIH Guidelines. The RG 
classification may change over time as additional information about 
the virus, such as potential treatments or the development of an 
effective vaccine, becomes available. 
Additional interim biosafety_guidance for research with SARS-CoV-2 
and IBC re~uirements under the NIH Guidelines 
Up next: Policy 
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